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Abstract
Background:  Commercial medium (Pharmamedia) was investigated for the production of
surfactin by Bacillus subtilis MZ-7. Different media (defined, semi-defined, and complex media) were
compared for the production of surfactin after fixing the least influential variables in standardized
fermentation conditions. Carbohydrate and nitrogen supplements were also tried to improve
production in Pharmamedia.
Results: Surfactin production was confirmed using PCR along with other analytical techniques and
monitored by RP-HPLC and MALDI-TOF-MS. We found that optimized and brain heart infusion
media were best for production of surfactin (280 mg/L) and a relatively comparable production
with Pharmamedia (220 mg/L), however, supplementing Pharmamedia with Fe+ (4.0 mM) and
sucrose (2 g/L) leads to a maximum production of about (300 mg/L).
Conclusion: Cottonseed-derived medium proved to be a suitable substrate for the production of
bioactive substances including surfactin, a useful compound in both medical and biotechnological
fields. The medium provided not only higher product accumulations but at considerably lower cost
with potential for large scale industrial applications.
1. Background
Bacillus subtilis strains produce a broad spectrum of bioac-
tive peptides with great potential for biotechnological and
biopharmaceutical applications. A well-known class of
such compounds includes the lipopeptides surfactin [1-
3], fengycin [4], and the iturin compounds [5] iturin A, B,
and C [6], mycosubtilins [7], and bacillomycins [8],
which are amphiphilic membrane-active biosurfactants
and peptide antibiotics with potent antimicrobial activi-
ties. Although surfactin was discovered four decades ago,
there has been a revival of interest, triggered by increasing
evidence for their medical effectiveness [9,10]. Surfactin
possessed antimicrobial [11-13], antiviral [14-16], antitu-
mor [17], hemolytic [18], blood anticoagulant, and fibri-
nolytic [19,18] activities. As one of the strongest
biosurfactants [20,21], surfactin has numerous environ-
mental and biotechnological applications [22] and has
shown particular utility in oil recovery [23,24], remedia-
tion of soil contaminated by heavy metals [25,26], and
biocontrol against phytopathogens [27,28] and insects
[29]. Diverse new properties have been recognized,
including emulsification, foaming [30], inhibition of star-
Published: 5 June 2007
Microbial Cell Factories 2007, 6:17 doi:10.1186/1475-2859-6-17
Received: 23 January 2007
Accepted: 5 June 2007
This article is available from: http://www.microbialcellfactories.com/content/6/1/17
© 2007 Al-Ajlani et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Microbial Cell Factories 2007, 6:17 http://www.microbialcellfactories.com/content/6/1/17
Page 2 of 8
(page number not for citation purposes)
fish oocyte maturation [31], and antimycoplasmic activi-
ties [32].
Despite many advantages of surfactins over chemical
agents and great recent advances in our understanding of
surfactins [33-37], there have been hardly any significant
applications of surfactins, mainly because of low strain
productivity and the need for expensive substrates
[38,39]. Efforts must therefore be redirected to improve
production efficiency and recovery bioprocesses in order
to optimize yields [38]. An earlier study carried out using
nutrient broth gave a very low yield (100 mg/L) [3]. A
minimal mineral salts medium was later defined, contain-
ing NH4NO3 (0.05 M) as the inorganic nitrogen source
and glucose (4%) as the carbon source (Cooper's
medium; [40]). Other studies have used a semisynthetic
medium (Landy's medium; [41]) that contains L-glutamic
acid (5 g/L) as the organic nitrogen source, glucose (2%)
as the carbon source, and trace metals [42,43], in one case
supplemented with 0.1% yeast extract and 2 mg/l pheny-
lalanine [15]. Optimizing the mineral requirement was
particularly beneficiary for the production of surfactin
[44,45,40]. Finally, potential substrates for surfactant pro-
duction have been sought that might provide cheaper and
renewable sources for economical production [38,46].
Interesting cheap sources have been described from
agroindustrial crops and residues, such as cassava [47],
soybean, sugar beet, potato [48,49], and sweet sorghum,
from crop residues such as bran and straw of wheat and
rice, and from waste derived from oil processing mills, for
example soy molasses from soybean processing and the
crude glycerol fraction from biodiesel production [50].
There have been no detailed reports concerning other
potentially economical substrates, most notably renewa-
ble resources, such as vegetable oils, distillery and dairy
wastes [51].
In this report, we describe surfactin production by two
producer strains and one non-producer strain of Bacillus
subtilis  in synthetic medium and cottonseed-derived
medium (Pharmamedia) and demonstrate the potential
of the latter to give similar yields as more expensive
media.
2. Materials and methods
2.1 Microorganisms
B. subtilis MZ-7 [52] is an environmental isolate (the
sequence of its 16S rRNA is found in accession no.
DQ327713). B. subtilis ATCC 21332 [3] and B. subtilis
subsp. subtilis  168 [53] are surfactin and non-surfactin
producers, respectively [54]. The later strain acted as a neg-
ative control in all experiments. Bacillus fusiformis NRS
613T was regularly used as a test organism. All strains
except strain MZ-7 were obtained from the Bacillus
Genetic Stock Center, Ohio, USA.
2.2. Media and culture condition
Pharmamedia (Traders Protein, USA) is an economical,
finely ground, yellow flour made from the embryo of cot-
tonseed. Its detail composition as provided by the manu-
facturer is listed in Table 1. Landy medium [41], Cooper's
medium [40], optimized medium [55], modified Landy
medium [55], and minimal salt medium [56] were made
as previously described. Sugars (2 g/L) and nitrogen sup-
plements (3 g/L) were made to the control medium. In all
cases, pre-inoculum was prepared by suspending in 10 ml
deionized water colonies taken from minimal salt agar.
The suspensions were adjusted to 5 × 1012cells per ml.
Growth temperature and pH values were maintained at
35°C and 7 ± 0.5, respectively. Fermentation was carried
out for 24 or 48 hours in 250 ml conical flasks containing
50 ± 5 mL broth on an orbital shaker operating at 120 rev/
min.
2.3. Growth measurement
Measurements of colony forming units were used to mon-
itor the time course of growth in culture, as the suspended
insoluble material in Pharmamedia made optical density
and dry weight measurements inconvenient. In compara-
tive experiments, cultures were passed through filter paper
to collect insoluble large particles and the filtrates were
passed through washed and preweighed micropore filters
(0.2 μm). The cell-loaded filters were dried at 105°C and
reweighed to determine the weights contributed by the
cell masses. The values were calibrated by the dry weight
of insoluble substances (such as iron sulfate) in fresh
(noninoculated) media. However, interference by con-
centrated iron salts on the measurement of cell dry weight
was negligible.
2.4. Detection and sequencing of sfp gene
A 675-bp fragment from the gene (sfp) from B. subtilis
encoding 4'-phosphopantetheinyl transferase [57], corre-
sponding positions 167–841 (GenBank accession no.
X63158), was targeted for amplification using two oligo-
nucleotides: P17 (5'-ATG AAG ATT TAC GGA ATT TA-3')
and P18 (5'-TTA TAA AAG CTC TTC GTA CG-3'). Amplifi-
cation was accomplished in a thermal cycler (Mastercy-
cler, Eppendorf, Germany) set for denaturing at 94°C for
1 min, annealing at 46°C for 30 s, and extension at 72°C
for 1 min, for a total of 25 cycles. PCR products were ana-
lyzed by 1.5% agarose gel electrophoresis. The purified
PCR products were sequenced by using an ABI Prism dye
terminator cycle sequencing ready reaction kit and an ABI
PRISM 377 DNA sequencer (Applied Biosystems, USA).
Analyses of DNA sequences were performed by using
Prochromas version software (Oxford Molecular, UK).Microbial Cell Factories 2007, 6:17 http://www.microbialcellfactories.com/content/6/1/17
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2.5 Quantification and qualification analysis
2.5.1 Isolation of surfactin
Crude surfactin was isolated by adding concentrated
hydrochloric acid to the broth after removing the biomass
by centrifugation. A precipitate was formed at pH 2 which
was collected, dried, and extracted with dichloromethane.
The solvent was removed under reduced pressure to give
an off-white solid. Further purification was achieved by
recrystallization. The dichloromethane extract was dis-
solved in distilled water containing sufficient NaOH to
produce a pH of 8. This solution was filtered through
Whatman filter paper No. 1 and titrated to pH 2 with con-
centrated HCl. The white solid was collected as a pellet
after centrifugation. Samples were scratched out from a
Table 1: Chemical characteristics of Pharmamedia
ANALYSIS (TYPICAL)
Total Solids 98.18%
Protein (N × 6.25) 58.76%
NFE (Carbohydrates) 24.13%
Reducing Sugars 1.18%
Nonreducing Sugars 1.16%
Fat (Linoleic, Oleic and
Palmitic Fatty Acids 4.25%
Ash 6.71%
Fiber 2.55%
Moisture 1.82%
Gossypol (A Yellow Pigment) 0.04%
pH (Aqueous Solution) 6.5
AMINO ACIDS
Lysine 4.44% Alanine 4.10%
Histidine 2.93% 1/2 Cystine 1.67%
Arginine 12.35% Valine 4.54%
Aspartic Acid 9.69% Methionine 1.57%
Threonine 3.47% Isoleusine 3.31%
Serine 4.77% Leucine 6.34%
Glutamic Acid 22.41% Tyrosine 2.87%
Proline 4.25% Phenylalanine 5.71%
Glycine 4.41% Tryptophan 1.17%
SOLUBLES
Total Solubles 37.20%
Soluble Amino Nitrogen 0.023%
Soluble Phosphorus (P) 0.702%
Soluble Iron (Fe) ND
Soluble Magnesium (Mg) 0.391%
MINERAL CONTENT (ppm)
Calcium (Ca) 1,900 Magnesium (Mg) 7,400
Chlorides (Cl) 470 Potassium (K) 5,200
Phosphorus (P) 14,000 Sodium (Na) 30
Iron (Fe) 80 ppm
VITAMIN CONTENT (μg/Gm)
Carotene <.10 Pantothenic Acid 12.40
Total Tocopherols 11.00 Choline 3,270.00
Ascorbic Acid 32.00 Pyridoxine 16.40
Thiamine 3.99 Biotin 1.52
Riboflavin 4.82 Folic Acid 1.59
Niacin 83.30 Inositol 10,800Microbial Cell Factories 2007, 6:17 http://www.microbialcellfactories.com/content/6/1/17
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nonsprayed thin layer chromotography (TLC) plate
extracted three times with methanol, and reduced by vac-
uum oven to a volume of 1 ml.
2.5.2 Quantitative analysis of surfactin by HPLC
Active fractions from TLC were further purified by
reversed-phase HPLC, using a Thermo Hypersil-Keystone
ODS (particle size, 5 μm; column dimensions, 250 by 4.6
mm; Thermo Hypersil, USA). A sample was applied with
eluent A (0.1% (vol/vol) trifluoroacetic acid and 20%
(vol/vol) acetonitrile) and eluted with segmented gradi-
ents of eluent B (0.1% (vol/vol) trifluoroacetic acid and
80% (vol/vol) acetonitrile) as follows: 40% eluent B for
30 min and 40 to 100% eluent B for 10 min. Eluents A
and B were made using Milli-Q HPLC grade water. The
concentration of surfactin was determined from a calibra-
tion curve made by correlating the emulsification index (E
24) with known amounts of surfactin produced by B. sub-
tilis ATCC 21332.
2.5.3. MALDI-TOF-mass spectrometry
Fractions correlated with surfactin from TLC and Reverse
phase HPLC were analyzed using MALDI-TOF-MS. 2 μL of
samples were mixed on the target plate with 2 μL of matrix
solution (2 mg of alpha-hydroxycinnaminic acid per ml
in acetonitrile-methanol-water, 1:1:1). MALDI-TOF-MS
spectra were recorded by using a 337-nm nitrogen laser
for desorption and ionization. The mass spectrometer was
operated in the refraction mode at an accelerating voltage
of 18 kV with an ion flight path that of 0.7 m. The delay
time was 375 ns. Matrix-suppression was also used, and
the mass spectra were averaged over 50 to 100 individual
laser shots. The laser intensity was set just above the
threshold for ion production. External calibration was
performed by using the [M+H]+ signals of renin, adeno-
corticotropic hormone, insulin oxidized B, and bovine
insulin (Sigma-Aldrich Co.). Surfactin isomers were antic-
ipated to have an m/z range of 500–1500. The variance of
the m/z of ± 0.8 Da was considered acceptable.
2.6. Statistical analysis
The data is presented in terms of arithmetic averages of at
least three replicates, and the error bars indicate the stand-
ard deviations. The analyses were carried out using SPSS
software, version 14.0 (SPSS Inc., Chicago, USA).
3. Results
3.1. Isolation and quantification of surfactin
The concentrated extracts run on silica TLC plates showed
six bands under UV light, having Rf values of 0.1, 0.15,
0.26, 0.37, 0.51 and 0.57. However, a plate bioassay
showed two active fractions, those with Rfvalues of 0.37
and 0.51. The spot with an Rf value of 0.51 was ninhydrin-
negative and positive to 4,4'-bis(dimehtylamino)diphe-
nylmethane (TDM) reagent. These results indicated the
absence of free amino groups and the presence of peptide
bonds in the compound. A white spot formed with the
same Rf value when the plate was sprayed with water, indi-
cating that the compound is lipophilic. The migration and
chemical properties of the compound were comparable to
surfactin produced by B. subtilis strain ATCC 21332. We
observed that the environmental isolate B. subtilis MZ-7
produced more surfactin (170.5 mg/L) than did B. subtilis
ATCC 21332 (109.5 mg/L) under the same conditions.
3.2. Detection of surfactin production by PCR
B. subtilis subsp. subtilis 168 was negative to specific prim-
ers for sfp genes. However, 675-bp fragments were ampli-
fied with genomic DNA of B. subtilis MZ-7 and B. subtilis
ATCC 21332 (Figure 1B). Sequence comparisons showed
99% similarity between these fragments and sfp genes in
the database from known surfactin producers [58].
3.3. Confirmation of surfactin by MALDI-TOF-MS
Running MALDI-TOF-MS in refractron mode, we
observed a cluster of peaks with mass/charge (m/z) ratios
between 1036 and 1058, which could be attributed to
protonated surfactin isoforms (Figure 1A). The peak with
a m/z ratio 1045.86 corresponds to the mass of [M+Na]+
ion of surfactin with a fatty acid chain length of 14 carbon
atoms [59]. Observed isomers of surfactin in different
media fermentations were more or less similar [60].
3.4. Standardization of optimal conditions for surfactin 
production
Figure 2 shows the relationship in Landy medium and
Pharmamedia between the density of B. subtilis MZ-7 cul-
tures and the pH of medium and shows the concentration
of an antimicrobial compound that appeared over the
time course of the incubation. In Landy medium, the con-
centration of the inhibitory compound was high at 24 h,
when the culture was in its post-exponential phase, and
reached its highest level at 44 h, i.e. at stationary phase.
However, in Pharmamedia, maximum concentration was
observed during the post-exponential phase (28 h), with
a decrease in production during the stationary phase of
the growth cycle. The optimum production time thus dif-
fers in Landy medium and Pharmamedia. The pH of cul-
ture was almost stable, ranging from 7 to 8.
3.5. Comparative production in different media
Among the laboratory media tested (Figure 3), B. subtilis
MZ-7 produced maximum surfactin in BHI and optimized
medium (260 mg/L), followed by Landy medium (240
mg/L). Relatively low yields (220 mg/L) were observed in
commercial medium (Pharmamedia) without any sup-
plementation. Addition of various carbon and nitrogen
sources were tested (Figure 4). It was observed that sucrose
supplementation caused a marked enhancement in sur-
factin production (280 mg/L), potentially significant withMicrobial Cell Factories 2007, 6:17 http://www.microbialcellfactories.com/content/6/1/17
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regards to the goal of large scale production of surfactin
on cheap media.
4. Discussion
Since its discovery, surfactin has proved to be an interest-
ing biochemical tool for basic research. On account of its
biodegradability and its broad range of functional proper-
ties, it is now evident that surfactin has potential applica-
tions in industrial processes, primarily those involving
surfactant activities. Thus, the interest of researchers is
warranted but, to date, surfactin has not been able to com-
pete economically with its chemically synthesized coun-
terparts because of poor strain productivity and the need
for expensive substrates. Efforts must therefore be redi-
rected to improve the production efficiency and recovery
bioprocesses in order to optimize yields. Most nutritional
and production studies have been done with batch cul-
tures, usually in shake flasks, but occasionally in small-
scale or large-scale fermentors [40,61-63]. A laboratory-
scale cyclone column fermentor was used for continuous,
phased growth with feedback control, based on the con-
centration of dissolved oxygen [64,65]. Saccharose and
fructose have also been mentioned as efficient carbon
sources, while the presence of glycerol greatly decreased
surfactin production [66]. In contrast to the biosynthesis
of other biosurfactants, surfactin biosynthesis was not
stimulated by hexadecane [40,43].
No notable difference in the ability of different amino
acids to support surfactin production has been found,
yields being 600–800 mg L-1 [43]. When they are used as
the sole nitrogen source of a culture medium, some
hydrophobic amino acids insert themselves directly into
selected positions of the peptide sequence, thus amplify-
ing the original structural microheterogeneity via the pro-
duction of variants [67].
In contrast to many secondary metabolites of bacilli, the
production of which is induced when the cells have
exhausted one or more essential nutrients, surfactin pro-
duction is induced in actively growing cells by progression
to postexponential phase [11]. In most of the available lit-
erature a combination of nutritional and physicochemical
factors giving the highest yields was selected for use. How-
ever, the use of effective commercial media was com-
pletely neglected until the last decades, when several
scientists showed interest in using more economical,
renewable sources for production [38,46]. In fact, cotton-
seed media have been reported to be cost-effective in the
production of several antibiotics and enzymes. The per-
A) Surfactin cluster + Na+ obtained by MALDI-TOF-MS B) Amplification of sfp fragments by PCR, using DNA from B. subtilis  168, B. subtilis strain ATCC 21332, B. subtilis MZ-7 (lanes 1, 2, and 3, respectively) Figure 1
A) Surfactin cluster + Na+ obtained by MALDI-TOF-MS B) Amplification of sfp fragments by PCR, using DNA from B. subtilis 
168, B. subtilis strain ATCC 21332, B. subtilis MZ-7 (lanes 1, 2, and 3, respectively).Microbial Cell Factories 2007, 6:17 http://www.microbialcellfactories.com/content/6/1/17
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formed experiments in this report were conducted in very
Time course of growth of B. subtilis MZ-7 on two growth media Figure 2
Time course of growth of B. subtilis MZ-7 on two growth media. Each point is the result of 3 measurements. The error bars 
show the standard deviation of the measurements. The following parameters were monitored: pH of the growth medium (▲), 
CFU (■), and ability of samples to inhibit the growth of B. fusiformis (❍).
Surfactin production by B. subtilis MZ-7 grown on different media Figure 3
Surfactin production by B. subtilis MZ-7 grown on different media. Each bar represents the average of 3 measurements, with 
error bars indicating the standard deviation. Media used were as described in Materials and Methods: Luria bretani (LB), Nutri-
ent broth (NB), Brain heart infusion (BHI), Optimized (Optm), Minimal salt (MS), Cooper (CM), Landy (Ln), Pharmamedia 
(PM), and Pharmamedia supplemented with 2 g/L sucrose and 4.0 mM Fe+ (PM+).Microbial Cell Factories 2007, 6:17 http://www.microbialcellfactories.com/content/6/1/17
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restricted conditions in favor of reproducibility and that is
to demonstrate a successful comparison not enhanced
production potential. As this paper did not show econom-
ical studies, it was left for industrial economists to estab-
lish such a relation.
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